Left Atrial Appendage Exclusion (LAAE) is recommended during heart surgery by The Society of Thoracic Surgeons, American College of Cardiology, and the American Heart Association
Over 20 years, our investments have led to over 14,000 patients studied in clinical research with AtriClip® devices, resulting in 85+ published studies.
As the device leader in LAA exclusion, see why surgeons across the globe are choosing AtriClip: https://t.co/GKo3HYrM88
Want to learn more about Hybrid AF™ Therapy? By attending the upcoming Hybrid AF Therapies Summit in Milan, Italy, you’ll be equipped with the knowledge and skills necessary to implement an effective hybrid #Afib ablation program. Register now: https://t.co/BxLyf4ZLRw.#Epeeps
Beta blockers & calcium channel blockers are commonly used for IST symptoms, but their effectiveness hasn’t been proven. The HEAL-IST Trial is testing a new hybrid ablation therapy for symptomatic, drug-refractory or intolerant #IST.https://t.co/Cw1e4NF5xM.
PM-US-3169A-0125-G
Two conditions that are likely to dominate the next 50 years of cardiovascular care are also increasing in prevalence.
Both affect millions of people and after age 40:
1 in 4 people will develop Afib
1 in 5 people will develop HF
1/2
While beta blockers or calcium channel blockers are often used as first-line therapy to treat symptoms of inappropriate sinus tachycardia, they haven’t been proven effective.
The HEAL-IST Trial is evaluating the safety and effectiveness of a new hybrid ablation therapy for symptomatic, drug-refractory or intolerant IST.
Visit https://okt.to/QyuP04 to learn more.
PM-US-3169A-0125-G
We honor and remember the brave men and women who made the ultimate sacrifice for our nation. Their courage and selflessness will forever be etched in our hearts and in the fabric of our country. Today, we stand united in gratitude and reverence for their service and sacrifice. #MemorialDay
Can preemptive LAA exclusion shield cardiac patients from future strokes? LeAAPS™ aims to evaluate whether individuals with elevated stroke risk but no Afib benefit from LAAE using AtriClip® devices.
Learn more: https://okt.to/PGnouK#StrokeAwarenessMonth #Stroke#LAAE
Over 80% of Afib cases are associated with high blood pressure. The good news? By managing your blood pressure through lifestyle changes and medications, you can reduce your risk. Talk to your doctor today for personalized guidance on keeping your blood pressure in a healthy range.
Learn more at https://okt.to/dPjgEY
Are you passionate about driving innovation in healthcare and making a real impact in patients' lives? Join us as a Hybrid Therapies Clinical Specialist where you'll play a pivotal role in advancing our mission by supporting surgeons during procedures, driving market development and awareness, and collaborating with customers.
If you are ready to join a dynamic, dedicated team, apply today!
https://okt.to/JomeVk
At AtriCure, we're dedicated to advancing healthcare through research, development, and clinical trials. Over 20 years, our investments have led to over 14,000 patients studied in clinical research with AtriClip® devices, resulting in 85+ published studies.
As the device leader in LAA exclusion, see why surgeons across the globe are choosing AtriClip: https://okt.to/7BSkQl#AtriClip#Cardiac#CardiacSurgery#LAAM
Want to learn more about Hybrid AF™ Therapy? By attending the upcoming Hybrid AF Therapies Summit in Milan, Italy, you’ll be equipped with the knowledge and skills necessary to implement an effective hybrid #Afib ablation program. Register now at: https://okt.to/QlMSiN.#Epeeps#HybridAFTherapy#meded
Centro Cardiologico Monzino
While beta blockers or calcium channel blockers are often used as first-line therapy to treat symptoms of inappropriate sinus tachycardia, they haven’t been proven effective.
The HEAL-IST Trial is evaluating the safety and effectiveness of a new hybrid ablation therapy for symptomatic, drug-refractory or intolerant IST.
Visit www.heal-ist.com to learn more.
#IST#innapropriatesinustachycardia#clinicaltrial
PM-US-3169A-0125-G
social media channels to keep updated on the latest at AtriCure.
Blake's Pectus Excavatum Journey: 2 Months Post-Op
Duration: 2:31
Blake's Pectus Excavatum Journey: Surgery
Duration: 2:49
Blake's Pectus Excavatum Journey: 1 Week Pre-Op
Duration: 3:41
Blake's Pectus Excavatum Journey: 1 Month Pre-Op
Duration: 2:58